Literature DB >> 12684743

Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity.

David Pubill1, Anna M Canudas, Mercè Pallàs, Antonio Camins, Jorge Camarasa, Elena Escubedo.   

Abstract

The consequences of the neurotoxic insult induced by 3,4-methylenedioxymethamphetamine (MDMA, an amphetamine derivative with specific action on the serotonergic system) were compared with those of methamphetamine (a derivative with specific action on dopaminergic system) in rats. Both drugs induced a very similar loss of body weight, especially evident 24 h after treatment. Their hyperthermic profile was also very similar and was dependent on ambient temperature, corroborating the thermo-dysregulatory effect of both substances. Methamphetamine (four injections of 10 mg kg(-1) s.c. at 2-h intervals) induced the loss of dopaminergic (35%) but not of serotonergic, terminals in the rat striatum and, simultaneously, a significant increase in striatal peripheral-type benzodiazepine receptor density, pointing to a glial reaction. Evidence for this drug-induced astrogliosis was the increased heat shock protein 27 (HSP27) expression in striatum, cortex and hippocampus. MDMA (20 mg kg(-1) s.c. b.i.d. for 4 days) induced a similar dopaminergic lesion in the striatum 3 days post-treatment, which reversed 4 days later. An important neurotoxic effect on serotonergic terminals was also observed in the cortex, striatum and hippocampus 3 days post-treatment, which partially reversed 4 days later in the striatum and hippocampus. No microglial activation was noticeable at either 3 or 7 days after MDMA treatment. This lack of effect on microglial cells was assessed by [(3)H]PK 11195 binding and OX-6 immunostaining, which were unchanged in the striatum and cortex after MDMA treatment. A non-significant tendency to increase was noted in the hippocampus 3 days after MDMA treatment. Furthermore, in MDMA-treated rats, neither HSP27 expression nor an increase in HSP27 immunoreactivity were detected. This result, together with the lack of increase in glial fibrilliary acidic protein (GFAP) immunoreactivity, indicate no astroglial activation at either 3 or 7 days post-treatment. Without microglial activation, an inflammatory process would not accompany the lesion induced by MDMA. The differences in glial activation between methamphetamine and MDMA observed in the present study could have implications for the prognosis of the injury induced by these drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12684743     DOI: 10.1007/s00210-003-0747-y

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  42 in total

1.  Differences between rats and mice in MDMA (methylenedioxymethylamphetamine) neurotoxicity.

Authors:  B J Logan; R Laverty; W D Sanderson; Y B Yee
Journal:  Eur J Pharmacol       Date:  1988-08-02       Impact factor: 4.432

Review 2.  Immune regulation within the central nervous system.

Authors:  B G Xiao; H Link
Journal:  J Neurol Sci       Date:  1998-04-15       Impact factor: 3.181

3.  Cellular and subcellular localization of peripheral benzodiazepine receptors after trimethyltin neurotoxicity.

Authors:  A C Kuhlmann; T R Guilarte
Journal:  J Neurochem       Date:  2000-04       Impact factor: 5.372

Review 4.  Peripheral benzodiazepine receptors and mitochondrial function.

Authors:  Pierre Casellas; Sylvaine Galiegue; Anthony S Basile
Journal:  Neurochem Int       Date:  2002-05       Impact factor: 3.921

5.  Rapid and reversible effects of methamphetamine on dopamine transporters.

Authors:  A E Fleckenstein; R R Metzger; D G Wilkins; J W Gibb; G R Hanson
Journal:  J Pharmacol Exp Ther       Date:  1997-08       Impact factor: 4.030

Review 6.  (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals.

Authors:  G A Ricaurte; J Yuan; U D McCann
Journal:  Neuropsychobiology       Date:  2000       Impact factor: 2.328

7.  Immunocytochemical study of an early microglial activation in ischemia.

Authors:  J Gehrmann; P Bonnekoh; T Miyazawa; K A Hossmann; G W Kreutzberg
Journal:  J Cereb Blood Flow Metab       Date:  1992-03       Impact factor: 6.200

8.  Region-selective effects of neuroinflammation and antioxidant treatment on peripheral benzodiazepine receptors and NMDA receptors in the rat brain.

Authors:  A Biegon; M Alvarado; T F Budinger; R Grossman; K Hensley; M S West; Y Kotake; M Ono; R A Floyd
Journal:  J Neurochem       Date:  2002-08       Impact factor: 5.372

9.  Peripheral type benzodiazepine binding sites are a sensitive indirect index of neuronal damage.

Authors:  J Benavides; D Fage; C Carter; B Scatton
Journal:  Brain Res       Date:  1987-09-22       Impact factor: 3.252

Review 10.  Neurochemical mechanism of action of anorectic drugs.

Authors:  R Samanin; S Garattini
Journal:  Pharmacol Toxicol       Date:  1993-08
View more
  40 in total

Review 1.  Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity?

Authors:  Mark J Niciu; Ioline D Henter; Gerard Sanacora; Carlos A Zarate
Journal:  World J Biol Psychiatry       Date:  2013-09-12       Impact factor: 4.132

Review 2.  Amphetamine toxicities: classical and emerging mechanisms.

Authors:  Bryan K Yamamoto; Anna Moszczynska; Gary A Gudelsky
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

Review 3.  The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies.

Authors:  Yosta Vegting; Liesbeth Reneman; Jan Booij
Journal:  Psychopharmacology (Berl)       Date:  2016-08-28       Impact factor: 4.530

Review 4.  Nucleus accumbens invulnerability to methamphetamine neurotoxicity.

Authors:  Donald M Kuhn; Mariana Angoa-Pérez; David M Thomas
Journal:  ILAR J       Date:  2011

5.  The Role of Glial Cells in Drug Abuse.

Authors:  Jose Javier Miguel-Hidalgo
Journal:  Curr Drug Abuse Rev       Date:  2009

6.  MDMA produces a delayed and sustained increase in the extracellular concentration of glutamate in the rat hippocampus.

Authors:  John H Anneken; Gary A Gudelsky
Journal:  Neuropharmacology       Date:  2012-07-25       Impact factor: 5.250

7.  The anti-inflammatory effect of melatonin on methamphetamine-induced proinflammatory mediators in human neuroblastoma dopamine SH-SY5Y cell lines.

Authors:  Kannika Permpoonputtana; Piyarat Govitrapong
Journal:  Neurotox Res       Date:  2012-08-18       Impact factor: 3.911

8.  Glial cell response to 3,4-(+/-)-methylenedioxymethamphetamine and its metabolites.

Authors:  Joseph M Herndon; Aram B Cholanians; Serrine S Lau; Terrence J Monks
Journal:  Toxicol Sci       Date:  2013-12-03       Impact factor: 4.849

9.  Assessing the role of dopamine in the differential neurotoxicity patterns of methamphetamine, mephedrone, methcathinone and 4-methylmethamphetamine.

Authors:  John H Anneken; Mariana Angoa-Perez; Girish C Sati; David Crich; Donald M Kuhn
Journal:  Neuropharmacology       Date:  2017-08-26       Impact factor: 5.250

10.  The danger-associated molecular pattern HMGB1 mediates the neuroinflammatory effects of methamphetamine.

Authors:  Matthew G Frank; Sweta Adhikary; Julia L Sobesky; Michael D Weber; Linda R Watkins; Steven F Maier
Journal:  Brain Behav Immun       Date:  2015-08-04       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.